Metastatic Castration-resistant Prostate Cancer Clinical Trials in Rochester, Minnesota

5 studies are recruiting for metastatic castration-resistant prostate cancer in Rochester, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mayo Clinic, Rochester, Minnesota
    Locations
    33 in total
    Run by
    Parabilis Medicines, Inc.
  2. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    Mayo Clinic, Rochester, Minnesota
    Locations
    36 in total
    Run by
    Janux Therapeutics
  3. A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

    Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant prostate cancer. The study aims to assess whether the drug is safe, increasing doses alone and in combination with darolutamide, whether it is effective …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mayo Clinic, Rochester, Minnesota
    Locations
    13 in total
    Run by
    K36 Therapeutics, Inc.
  4. A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

    The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Rochester, Minnesota
    Locations
    16 in total
    Run by
    AstraZeneca
  5. A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

    The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter identified as AAA617) in taxane-naïve adult participants with P…

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    Mayo Clinic Rochester, Rochester, Minnesota
    Locations
    21 in total
    Run by
    Novartis Pharmaceuticals

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.